US 12,076,409 B2
Polymer-drug conjugates for combination anticancer therapy
Kathryn M. Camacho, Los Angeles, CA (US); Stefano Menegatti, Raleigh, NC (US); Sunny Kumar, Aliso Viejo, CA (US); Douglas Vogus, Goleta, CA (US); and Samir Mitragotri, Lexington, MA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/546,480.
Application 17/546,480 is a division of application No. 16/846,707, filed on Apr. 13, 2020, granted, now 11,197,932.
Application 16/846,707 is a continuation of application No. 15/556,798, granted, now 10,653,789, issued on Sep. 8, 2017, previously published as PCT/US2016/021587, filed on Mar. 9, 2016.
Claims priority of provisional application 62/130,284, filed on Mar. 9, 2015.
Prior Publication US 2022/0096645 A1, Mar. 31, 2022
Int. Cl. A61K 47/61 (2017.01); A61K 31/4745 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01)
CPC A61K 47/61 (2017.08) [A61K 31/4745 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01)] 23 Claims
 
1. A method of treating cancer in a patient comprising administering to the patient a pharmaceutical composition comprising doxorubicin and camptothecin conjugated to a biocompatible polymer;
wherein the doxorubicin and camptothecin are conjugated to the biocompatible polymer directly via covalent bonds or indirectly via linkers; and
wherein at least one of the doxorubicin and camptothecin are conjugated to the biocompatible polymer directly via covalent bonds.